Key points
- Reported a net loss of $9,089,281 for the year ended 30 June 2026
- Cash balance at 30 June 2026 was $897,418
- No significant differences in efficacy between control and active groups in clinical trials
- The company made all employee positions redundant to reduce costs
- Entered into a R&D TI loan facility of $600,000
Full summary
Cynata Therapeutics Limited reported a net loss of $9,089,281 for the financial year ended 30 June 2026, compared to a loss of $9,390,586 in the previous year. The company's cash balance stood at $897,418 at the end of the financial year, down from $5,049,744 in the previous year. The company announced the primary evaluation results of the Phase 2 clinical trial of CYP-001 in patients with high-risk acute graft versus host disease (HR-aGvHD) and the top-line results of the Phase 3 clinical trial of CYP-004 in osteoarthritis. There were no safety concerns identified in these trials, but no significant differences between the control and active groups in the primary or key secondary efficacy endpoints. The company made all of its employee positions redundant to reduce costs significantly, including the position of Chief Executive Officer and Managing Director. The company also entered into a Research and Development Tax Incentive (R&D TI) loan facility of $600,000 with a commercial lender, secured against the assets of the company including the anticipated FY26 R&D TI rebate (expected to be approximately $1.7 million).
Guidance
Net loss for the year: $9,089,281 (2025: $9,390,586)
Outlook
The company has limited financial resources and does not currently generate operating revenue to fund material development activities. Its ability to execute its strategy will depend on careful management of its existing resources and access to additional funding.